No Detail Found!

A Comparative Study of Cisplatin Plus Adriamycin Compared with Cyclophos- phamide Plus Adriamycin in Patients with Untreated Metastatic TNBC

Author(s)
Sobia Yaqub Department of Oncology, King Edward Medical University, Pakistan
Muhammad Abbas Khokhar Department of Oncology, King Edward Medical University, Pakistan
Amjad Zafar Department of Oncology, Jinnah Hospital Lahore, Pakistan
Ali Waheed Goraya Department of Oncology, King Edward Medical University, Pakistan
Aqsa Rauf Department of Oncology, Jinnah Hospital Lahore, Pakistan
Zeeshan Ahmed Khan Niazi Department of Oncology, King Edward Medical University, Pakistan
Abstract
Objective: To look for the response of platinum agents in BRCA unknown TNBC patients as it is a cheaper drug and readily available. Material and Methods: This study was comparative, conducted in department of Medical Oncology and Radiotherapy from May 2019 to Februaray 2021 in which a total of 290 (145 in each arm) patients of metastatic TNBC were enrolled. A total of 290 patients (145 in each arm) of symptomatic metastatic TNBC were randomized into 2 groups. Group A received Adriamycin (60mg/m²) plus Cisplatin (75mg/m²) while Group B received Adriamycin (60mg/m²) plus Cyclophosphamide (600mg/m²) on day 1 of 21 days cycle for a total of 4 cycles. The response was assessed using RECIST criteria v.1.01. National Cancer Institute Common Toxicity Criteria version 4.03 (CTCAE) was used to document toxicities. Health-related quality of life was determined using EORTC QLQ- C30 with a minimum decrease of =10 points considered significant. Data was analyzed using spss version 23. The quantitative variables were presented as mean ±SD while qualitative variables like tumor response as percentage and frequency. An Independent sample t-test with a confidence interval of 95% was used for comparison between groups and a p-value of < 0.05 was taken as significant. Results: In group A, 33(22.8%) and 67(46.2%) showed complete and partial responses respectively while stable and progressive disease was noted in 25(17.2%) and 20(13.8%). In group B, 23(15.9%) had complete response while 66(45.5%), 41(28.3%), and 15(10.3%), showed partial response, stable and progressive disease respectively (p=0.094) ORR between groups was 69.0% vs.61.4%. More grade ¾ neuropathy (p=0.004) and nephropathy (p=0.00007) was seen in group A. Quality of life was comparable in both groups(p=0.540) Conclusions: No statistically significant difference in noted between two treatment arms but patients in the Cisplatin arm experienced more neuropathy and nephropathy.
Publication Details
Page(s) 355-358
Published Journal: ESCULAPIO. JOURNAL OF SERVICES INSTITUTE OF MEDICAL SCIENCES, Volume: 19, Issue: 3, Year: 2023

Request the full text from PASTIC

Keywords
Cisplatin, TNBC, metastatic
0

Citations

0

Downloads

177

Views